New cocktail aims to shrink rectal tumors before surgery
NCT ID NCT05731726
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with a certain type of locally advanced rectal cancer (pMMR/MSS) that often doesn't respond well to immunotherapy alone. The trial combines an immunotherapy drug (serplulimab) with chemotherapy (CAPEOX) and an anti-inflammatory drug (celecoxib) to see if this mix can shrink tumors more effectively before surgery. About 50 adults will take part to measure how many achieve a complete disappearance of cancer cells in the removed tissue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Second Affiliated Hospital School of Medicine Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- Can a Triple-Drug rechallenge tame colorectal cancer?
- New cocktail approach aims to wipe out High-Risk rectal cancer without surgery
- Intermittent fasting tested to ease radiation side effects in cancer patients
- New adaptive radiation boosts rectal cancer response rates
- New combo therapy aims to boost survival in tough rectal cancer